The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency’s seal of approval.
The WHO said it granted emergency use listing (EUL) authorization to the LC16m8 vaccine to “facilitate increased and timely access to vaccines in communities where mpox outbreaks are surging”.
A WHO EUL paves the way for countries worldwide to quickly approve and import the vaccine for distribution.
“WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children,” Yukiko Nakatani, WHO’s assistant director-general for access to medicines and health products, said in a statement.
The WHO had already in September prequalified another vaccine against mpox, Bavarian-Nordic’s MVA-BN, in a bid to help step up the fight against swelling mpox outbreaks.
The UN health agency on August 14 declared a fresh international emergency over mpox, amid mounting concern over a surge in cases of the new Clade 1b strain in the Democratic Republic of Congo that spread to nearby countries.
That and other mpox strains have been reported across 80 countries—19 of them in Africa—so far this year, WHO said.
The DR Congo remains by far the hardest-hit country, having recorded a large majority of the more than 39,000 suspected cases and over 1,000 deaths.
WHO said that Tuesday’s announcement was particularly relevant since the Japanese government had announced it would donate 3.05 million LC16m8 doses along with specialized inoculation needles to the DRC.
“This is the largest donation package announced to date in response to the current mpox emergency,” it said.
The WHO warned the vaccine should not be used during pregnancy or by immunocompromised persons.
Mpox, previously known as monkeypox, is caused by a virus transmitted to humans by infected animals but can also be passed from human to human through close physical contact.
It causes fever, muscular aches and large boil-like skin lesions, and can be deadly.
© 2024 AFP
Citation:
WHO approves second mpox vaccine (2024, November 20)
retrieved 20 November 2024
from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
The World Health Organization on Tuesday approved an mpox vaccine from Japanese pharma company KM Biologics for emergency use, the second one to get the agency’s seal of approval. The WHO said it granted emergency use listing (EUL) authorization to the LC16m8 vaccine to “facilitate increased and timely access to vaccines in communities where mpox outbreaks are surging”. A WHO EUL paves the way for countries worldwide to quickly approve and import the vaccine for distribution. “WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children,” Yukiko Nakatani, WHO’s assistant director-general for access to medicines and health products, said in a statement. The WHO had already in September prequalified another vaccine against mpox, Bavarian-Nordic’s MVA-BN, in a bid to help step up the fight against swelling mpox outbreaks. The UN health agency on August 14 declared a fresh international emergency over mpox, amid mounting concern over a surge in cases of the new Clade 1b strain in the Democratic Republic of Congo that spread to nearby countries. That and other mpox strains have been reported across 80 countries—19 of them in Africa—so far this year, WHO said. The DR Congo remains by far the hardest-hit country, having recorded a large majority of the more than 39,000 suspected cases and over 1,000 deaths. WHO said that Tuesday’s announcement was particularly relevant since the Japanese government had announced it would donate 3.05 million LC16m8 doses along with specialized inoculation needles to the DRC. “This is the largest donation package announced to date in response to the current mpox emergency,” it said. The WHO warned the vaccine should not be used during pregnancy or by immunocompromised persons. Mpox, previously known as monkeypox, is caused by a virus transmitted to humans by infected animals but can also be passed from human to human through close physical contact. It causes fever, muscular aches and large boil-like skin lesions, and can be deadly. © 2024 AFP Citation: This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
WHO approves second mpox vaccine (2024, November 20)
retrieved 20 November 2024
from
part may be reproduced without the written permission. The content is provided for information purposes only.
